Logo

SyntheticGestalt and Enamine Partner to Create AI-Based Model for Drug Discovery

Share this
SyntheticGestalt

SyntheticGestalt and Enamine Partner to Create AI-Based Model for Drug Discovery

Shots:

  • SyntheticGestalt and Enamine have collaborated for the creation of a suite of AI models to generate synthetically accessible, biologically active compounds with optimized physicochemical and ADME/Tox properties for effective compound discovery
  • Under the collaboration, SyntheticGestalt will have access to Enamine’s REAL database, consisting of 38 billion molecules, to develop a pre-trained AI model for predicting physicochemical and ADME/Tox properties of compounds
  • Enamine, through its in-house testing, will synthesize the chosen compounds within just 3-4wks. and provide quality pharmacological in vitro profiling data to expedite and shorten the discovery cycle

Ref: SyntheticGestalt | Image: SyntheticGestalt

Related News:- BioMap Collaborated with Sanofi to Co-Develop AI Modules to Advance Drug Discovery for Biotherapeutics Using BioMap’s AI Platform

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Shivani Chandra

Shivani was a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She was covering news related to Product approvals, clinical trial results, and updates. We can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions